More Nexalis Therapeutics Limited news
Nexalis Therapeutics LimitedASX: NX1

Amended Appendix 4C - Cash balance at 31/3 $3.904M

Apr 30, 2018 at 12:59 AM EDT · Issued by Nexalis Therapeutics Limited

Filed with ASX · Apr 30, 2018 at 12:59 AM EDT

On 6ix: 6ix.com/news/amended-appendix-4c-cash-balance-at-313-dollar3.904m

Nexalis Therapeutics Limited has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Nexalis Therapeutics Limited on 6ix

Earlier from Nexalis Therapeutics

  • Update on development of unique cannabis vaporizerApr 13, 2018
  • New Patient Self-Management System LaunchedMar 20, 2018
  • Lifespot Health restructures its Business and BoardNov 1, 2017
  • Lifespot Signs Global Agreement With BeurerSep 7, 2017
  • Digital Health Consortium Formed To Target $3.5B MarketJul 28, 2017

Later from Nexalis Therapeutics

  • Unique cannabis vaporizer under evaluation in IsraelMay 13, 2018
  • B.Braun to launch Omnitest 5 BT with Body-TelJun 4, 2018
  • LSH in discussions to finance integrated cannabis producersJun 19, 2018
  • Update on Unique Cannabis Vaporiser launch and BodytelAug 16, 2018
  • Lifespot Strengthens Go-To-Market Cannabis StrategySep 18, 2018
All Nexalis Therapeutics news releases↗

Follow Nexalis Therapeutics into a list and get an email when it puts out news.

Follow Nexalis Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer